![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Asia Pacific Virology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Test, Viral Infection Controlling Techniques, Antiviral Therapeutics, and Interferons), Application (Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Pharmaceutical and Biotechnological Companies, and Research and Academic Institutes)
Asia Pacific consists of five major countries namely China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The market is also evaluated for the rest of countries in Asia Pacific. The market is driven by the factors such as large population countries such as China and India, increasing focus of market players on this region, and introduction of new products in the country. Moreover, increasing incidences of influenza, HIV, and other infectious diseases are driving the market growth. In addition, growing awareness on better treatment procedures and advancement in technology, increased in healthcare spending and availability of advanced technology helps to boost the growth of virology market in the region. Surging growth in emerging economies is the major factor driving the growth of the APAC virology market.
COVID-19 has created an unprecedented public health emergency globally. It has demonstrated, emerging infectious diseases represent an existential threat worldwide. Rapid urbanization, deforestation, intensive agriculture, livestock rearing practices, and globalization are increasing opportunities for animal-to-human contacts and epidemics in the region. Urbanization is creating greater potential for epidemics and pandemics, as a large population now lives in cities. In addition, many countries were able to contain the COVID-19 based on previous epidemics. For instance, the South Korean central government began investing in domestic R&D of diagnostic reagents necessary for infectious disease testing. From 2017, it has invested approximately US$ 25 million in infectious disease diagnosis technology. The testing technologies developed by commercial manufacturers through government investments in R&D, including artificial intelligence (AI), proved critical for the government’s rapid launch of an effective COVID-19 response strategy. However, The COVID-19 pandemic has had a major impact on the essential HIV health services in the South East Asia Region, putting the growth at risk over the last two decades. COVID-19 has disrupted essential services causing considerable delays in the delivery of medicines and other health commodities. Changing priorities for HIV clinics and healthcare workers, travel restrictions, non-availability of public and limited private transportation, and worsening socio-economic contexts affected the continuity of essential HIV services. In the Philippines, more than 70% of delays or reductions in the number of visits to HIV clinics have been recorded since the pandemic, according to a survey conducted by Gilead Sciences. HIV and AIDS represented the most recent global pandemic, and the Global Fund has made enormous progress over the past 20 years. According to the study, over 82% of prescribers in India reported a decrease or delay of visits of people living with HIV. COVID-19 has also negatively impacted the uptake of HIV tests, and around 46% of the at-risk population reported a decrease in taking HIV tests during COVID-19. The main reasons for reduced testing were exposure to COVID-19 (62%) and travel restrictions (46%), as HIV tests were mostly only accessible at point-of-care. Therefore, it has negatively affected HIV care and other virus infections.
![](https://www.theinsightpartners.com//assets/rdimages/25450-img1.png)
Get more information on this report :
Market Overview and Dynamics
The virology market in APAC is expected to grow from US$ 931.92 million in 2021 to US$ 1,234.44 million by 2028; it is estimated to grow at a CAGR of 4.1% from 2021 to 2028. Viral infection is among the leading causes of human chronic diseases. A few viruses, such as human immunodeficiency virus (HIV), flu virus, Zika, Diphtheria, Ebola, SARS-CoV-2 (COVID-19), Polio, and Tetanus (Lockjaw), infect large populations across the world. As virus mutate and evolve continuously, drug resistance become an impending challenge for viral infection management among the human and animals. A virus transmits through various mediums based on its type. For instance, some viruses cause respiratory viral diseases, such as flu, common cold, and respiratory syncytial virus infection, transmits through droplets generated through coughing or sneezing; while some because gastrointestinal viral diseases transmitted through feces contaminated food or water. As per the UN Aids HIV & AIDS statistics, more than 37.7 million people across the world were infected by HIV in 2020. The novel coronavirus that causes COVID-19 was identified in 2019. The International Committee on Taxonomy of Viruses (ICTV) declared the virus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on February 11, 2020, and later WHO named the disease as COVID-19. The virus has undergone mutation a couple of times since its outbreak, which has added to the severity of the COVID-19 pandemic. Therefore, the rising prevalence of viral infections drives the growth of the APAC virology market.
Key Market Segments
The APAC virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020, and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segmented is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virology market in APAC are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.
Reasons to buy report
- To understand the APAC virology market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for APAC virology market
- Efficiently plan M&A and partnership deals in APAC virology market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form APAC virology market
- Obtain market revenue forecast for market by various segments from 2021-2028 in APAC region.
APAC Virology Market Segmentation
APAC Virology Market -By Type
- Diagnostic Test
- DNA Virus Testing
- RNA Virus Testing
- Others
- Viral Infection Controlling Techniques
- Active Prophylaxis
- Passive Prophylaxis
- Antiviral Therapeutics
- Virucidal Agents
- Antiviral Agents
- Immunomodulators
- Interferons
APAC Virology Market -By Application
- Skin and Soft Tissue Infections
- Respiratory Tract Infections
- GI Tract Infections
- Sexually Transmitted Diseases
- Urinary Tract Infections
- Others
APAC Virology Market -By End User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical and Biotechnological Companies
- Research and Academic Institutes
APAC Virology Market -By Country
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
APAC Virology Market -Company Profiles
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Virology Market – By Type
1.3.2 APAC Virology Market – By Application
1.3.3 APAC Virology Market – By End User
1.3.4 APAC Virology Market– By Country
2. APAC Virology Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Virology Market– Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Virology Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Viral Infectious Diseases
5.1.2 Increasing Product Launches
5.2 Market Restraints
5.2.1 Availability of Alternative Products and High Cost of Production of Products
5.3 Market Opportunities
5.3.1 Surging Growth in Several Economies
5.4 Future Trends
5.4.1 Continuous Demand for Cost-Effective Products
5.5 Impact Analysis
6. Virology Market– APAC Analysis
6.1 APAC Virology Market Revenue Forecast and Analysis
7. APAC Virology Market Analysis – By Type
7.1 Overview
7.2 APAC Virology Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Test
7.3.1 Overview
7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing
7.3.2.1.1 Overview
7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Ribonucleic Acid (RNA) Virus Testing
7.3.2.2.1 Overview
7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Others
7.3.2.3.1 Overview
7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Viral Infection Controlling Techniques
7.4.1 Overview
7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Active Prophylaxis
7.4.2.1.1 Overview
7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Passive Prophylaxis
7.4.2.2.1 Overview
7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Antiviral Therapeutics
7.5.1 Overview
7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Virucidal Agents
7.5.2.1.1 Overview
7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Antiviral Agents
7.5.2.2.1 Overview
7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Immunomodulators
7.5.2.3.1 Overview
7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Interferons
7.6.1 Overview
7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8. APAC Virology Market Analysis – By Application
8.1 Overview
8.2 APAC Virology Market, by Application 2021 & 2028 (%)
8.3 Skin and Soft Tissue Infections
8.3.1 Overview
8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Respiratory Tract Infections
8.4.1 Overview
8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.5 GI Tract Infections
8.5.1 Overview
8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Sexually Transmitted Diseases
8.6.1 Overview
8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9. APAC Virology Market Analysis – By End User
9.1 Overview
9.2 APAC Virology Market Revenue Share, by End User (2021 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Pharmaceutical and Biotechnological Companies
9.5.1 Overview
9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Research and Academic Institutes
9.6.1 Overview
9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
10. APAC Virology Market – Country Analysis
10.1.1 Overview
10.1.2 Asia Pacific: Virology Market, by Country, 2021 & 2028 (%)
10.1.2.1 China: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 China: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 China: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.1.2.1 China: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.1.2.2 China: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.1.2.3 China: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.1.3 China: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 China: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Japan: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Japan: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Japan: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.2.2.1 Japan: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.2.2.2 Japan: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.2.2.3 Japan: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.2.3 Japan: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 Japan: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.3 India: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 India: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 India: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.3.2.1 India: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.3.2.2 India: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.3.2.3 India: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.3.3 India: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 India: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.4 South Korea: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 South Korea: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2 South Korea: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.4.2.1 South Korea: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.4.2.2 South Korea: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.4.2.3 South Korea: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.4.3 South Korea: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.4.4 South Korea: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.5 Australia: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.1 Australia: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.2 Australia: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.5.2.1 Australia: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.5.2.2 Australia: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.5.2.3 Australia: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.5.3 Australia: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.5.4 Australia: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.6 Rest of Asia Pacific: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.1 Rest of Asia Pacific: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.2 Rest of Asia Pacific: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.6.2.1 Rest of Asia Pacific: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.6.2.2 Rest of Asia Pacific: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.6.2.3 Rest of Asia Pacific: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.6.3 Rest of Asia Pacific: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.6.4 Rest of Asia Pacific: Virology Market, by End User, 2019–2028 (USD Million)
11. Impact of COVID-19 Pandemic on APAC Virology Market
11.1 Overview
12. APAC Virology Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Johnson and Johnson Services, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. HOFFMANN-LA ROCHE LTD.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 QIAGEN
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Illumina, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 GlaxoSmithKline Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AbbVie Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gilead Sciences, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Virology Market Revenue and Forecast to 2028 (US$ Million)
Table 2. China: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. China Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 4. China Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 5. China Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 6. China: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 7. China: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 8. Japan: Virology Market, By Type– Revenue and Forecast to 2028 (USD Million)
Table 9. Japan Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 10. Japan Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 11. Japan Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 12. Japan: Virology Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 13. Japan: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 14. India: Virology Market, By Type– Revenue and Forecast to 2028 (USD Million)
Table 15. India Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 16. India Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 17. India Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 18. India: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 19. India: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 20. South Korea: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 21. South Korea Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 22. South Korea Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 23. South Korea Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 24. South Korea: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 26. Australia: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 27. Australia Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 28. Australia Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 29. Australia Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 30. Australia: Virology Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 31. Australia: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 32. Rest of Asia Pacific: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 33. Rest of Asia Pacific Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 34. Rest of Asia Pacific Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 35. Rest of Asia Pacific Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 36. Rest of Asia Pacific: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Asia Pacific: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 38. Organic Developments Done by Companies
Table 39. Inorganic Developments Done by Companies
Table 40. Glossary of Terms, APAC Virology Market
LIST OF FIGURES
Figure 1. APAC Virology Market Segmentation
Figure 2. APAC Virology Segmentation, By Country
Figure 3. APAC Virology Market Overview
Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in APAC Virology Market
Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in APAC Virology Market
Figure 6. India to Show Significant Growth During Forecast Period
Figure 7. APAC PEST Analysis
Figure 8. APAC Virology Market: Impact Analysis of Drivers and Restraints
Figure 9. APAC Virology Market– Revenue Forecast and Analysis – 2019- 2028
Figure 10. APAC Virology Market Revenue Share, by Type (2021 and 2028)
Figure 11. APAC Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. APAC DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. APAC RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. APAC Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. APAC Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. APAC Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. APAC Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. APAC Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. APAC Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. APAC Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. APAC Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. APAC Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. APAC Virology Market, by Application 2021 & 2028 (%)
Figure 24. APAC Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. APAC Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. APAC GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. APAC Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. APAC Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. APAC Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. APAC Virology Market Revenue Share, by End User (2021 and 2028)
Figure 31. APAC Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. APAC Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. APAC Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. APAC Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Asia Pacific: Virology Market, by Key Country – Revenue (2021) (USD Million)
Figure 36. Asia Pacific: Virology Market, by Country, 2021 & 2028 (%)
Figure 37. China: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Japan: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. India: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. South Korea: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Australia: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 42. Rest of Asia Pacific: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 43. Impact of COVID-19 Pandemic on Virology Market in APAC Countries
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the APAC Virology market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the APAC Virology market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the Virology market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution